AG
AGNPF.US Algernon Pharmaceuticals Inc
- Market cap
- USD 2.51M
- P/E
- -
- P/B
- 3.16x
- ROE
- -136.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is AGNPF.US undervalued?
Graham numberThe Graham number of Algernon Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Algernon Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Algernon Pharmaceuticals Inc yet.
Algernon Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Algernon Pharmaceuticals Inc
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada, the United States, and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was for…
Full company profileAlgernon Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Algernon Pharmaceuticals Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.93M | -1.45M | -949K | -1.91M | -8.68M | -8.05M | -6.06M | -5.24M | -2.41M | -1.72M | -2.21M |
| EBITDA | - | -1.32M | -908K | -1.89M | - | - | -6.02M | -5.19M | -2.39M | -1.66M | -2.22M |
| Net Income | -6.88M | -1.89M | -938K | -1.90M | -8.54M | -7.73M | -6.05M | -6.78M | -503K | -1.72M | -2.40M |
| EPS | - | -0.07 | -0.03 | -0.04 | -0.06 | -4.62 | -2.57 | -4.30 | -0.18 | -0.50 | -0.44 |
| Balance Sheet | |||||||||||
| Total Assets | 2.27M | 1.64M | 1.42M | 5.34M | 12.8M | 10.1M | 8.14M | 4.19M | 3.94M | 4.88M | 5.28M |
| Total Liabilities | 150K | 47.8K | 57.0K | 365K | 607K | 1.02M | 2.52M | 2.72M | 1.78M | 2.18M | 3.52M |
| Shareholders' Equity | 2.12M | 1.59M | 1.37M | 4.97M | 12.2M | 9.12M | 5.62M | 1.47M | 2.17M | 2.70M | 1.75M |
| Cash & Short-term Investments | 1.60M | 1.39M | 1.25M | 208K | 6.12M | 2.41M | 1.41M | 125K | 596K | 177K | 41.7K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.41M | -1.22M | -617K | -1.78M | -6.61M | -7.82M | -2.91M | -2.55M | -2.71M | -1.16M | -1.29M |
| Capital Expenditure | 128K | 86.6K | 0.00 | 65.7K | 99.7K | 124K | 145K | 59.5K | 84.0K | 25.0K | 13.4K |
| Free Cash Flow | - | -1.31M | -617K | -1.85M | -6.71M | -7.95M | -3.06M | -2.61M | -2.79M | -1.18M | -1.32M |
| Ratios | |||||||||||
| ROE | -324.0% | -119.0% | -68.6% | -38.1% | -69.9% | -84.8% | -107.6% | -460.1% | -23.2% | -63.7% | -136.8% |
| ROA | -302.5% | -115.5% | -65.9% | -35.5% | -66.6% | -76.3% | -74.4% | -161.7% | -12.8% | -35.2% | -45.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Algernon Pharmaceuticals Inc dividends
Algernon Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 21, 2026.
Who owns Algernon Pharmaceuticals Inc
- Insiders 5.61%
- Institutions 14.40%
- Public & others 79.98%
- Shares outstanding 9.64M
- Free float 7.20M
Algernon Pharmaceuticals Inc company profile
- Company name
- Algernon Pharmaceuticals Inc
- Ticker
- AGNPF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- August
- Address
- 601 West Broadway, Vancouver, BC, Canada, V5Z 4C2
- Phone
- 604 398 4175
- Website
- greymatters-health.com
About Algernon Pharmaceuticals Inc
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada, the United States, and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Algernon Pharmaceuticals Inc management
4- Mr. Christopher J. MoreauCEO & Director · born 1965
- Mr. James F. Kinley C.A., CPACFO & Corporate Secretary · born 1978
- Dr. Christopher Bryan Ph.D.Vice President of Research & Operations · born 1983
- Mr. Paul Joseph MoreauChief Marketing & Communications Officer